a6194t

Indicateby check mark whether the registrant files or will file annualreports under cover of Form 20-F or Form 40-F.

Indicateby check mark if the registrant is submitting the Form 6-K in paperas permitted by Regulation S-T Rule 101(b)(1):

Indicateby check mark if the registrant is submitting the Form 6-K in paperas permitted by Regulation S-T Rule 101(b)(7): ______

Indicateby check mark whether the registrant by furnishing the informationcontained in this Form is also thereby furnishing the informationto the Commission pursuant to Rule 12g3-2(b) under the SecuritiesExchange Act of 1934.

If“Yes” is marked, indicate below the file numberassigned to the Registrant in connection with Rule 12g3-2(b):82-_____________

Thefollowing notification is made in accordance with the UK FinancialConduct Authority's Disclosure and Transparency Rule 5.6.1. As at31 July 2025 the issued share capital of AstraZeneca PLC withvoting rights is 1,550,682,580 ordinary shares of US$0.25. Noshares are held in Treasury. Therefore, the total number of votingrights in AstraZeneca PLC is 1,550,682,580.

Theabove figure for the total number of voting rights may be used byshareholders as the denominator for the calculations by which theywill determine if they are required to notify their interest in, ora change to their interest in, AstraZeneca PLC under the UKFinancial Conduct Authority's Disclosure and TransparencyRules.

AstraZeneca(LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceuticalcompany that focuses on the discovery, development, andcommercialisation of prescription medicines in Oncology, RareDiseases, and BioPharmaceuticals, including Cardiovascular, Renal& Metabolism, and Respiratory & Immunology. Based inCambridge, UK, AstraZeneca's innovative medicines are sold in morethan 125 countries and used by millions of patients worldwide.Please visit astrazeneca.com andfollow the Company on social media @AstraZeneca

For details on howto contact the Investor Relations Team, pleaseclick here. For Mediacontacts, click here.

Pursuantto the requirements of the Securities Exchange Act of 1934, theRegistrant has duly caused this report to be signed on its behalfby the undersigned, thereunto duly authorized.

	By: /s/Matthew Bowden
	Name:Matthew Bowden
	Title:Company Secretary